Runhe Biology Medicine Technology (Shantou) Co., Ltd.

To investigate the pharmacokinetic characteristics of a single application of one flurbiprofen gel patch provided by Guangdong Econas Biopharmaceuticals Co., Ltd. [test preparation T, specification: each patch contains 40 mg flurbiprofen (area 13.6 cm × 10.0 cm, paste content 12 g)] or a flurbiprofen gel patch produced by Mikasa Seiyaku Co., Ltd. (reference preparation R, specification: each patch contains 40 mg flurbiprofen (area 13.6 cm × 10.0 cm, paste content 12 g)] to healthy subjects, evaluate the bioequivalence and safety of the two preparations, and investigate the adhesion of the two preparations, so as to provide a basis for the registration application of the test preparation.

To evaluate the pharmacokinetics and pharmacodynamics of the levonorgestrel ethinyl estradiol transdermal contraceptive patch in Chinese female subjects, and then rationalize the specifications, ratios and dosages of this patch to provide data basis for subsequent trials.

The purpose of this trial is to evaluate the pharmacokinetics of the levonorgestrel ethinyl estradiol transdermal contraceptive patch in Chinese female subjects, and then to rationalize the specifications, ratio and dosage of this patch and provide data basis for subsequent trials.